Hanmi Pharmaceutical Co., Ltd. 13D and 13G filings for :
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-20 8:54 pm Sale |
2025-03-18 | 13D | Aptose Biosciences Inc. APTO |
Hanmi Pharmaceutical Co., Ltd. | 508,710 19.900% |
-2,480,705 (-82.98%) |
Filing |
| 2024-04-26 12:54 pm Unchanged |
2024-04-24 | 13D | Aptose Biosciences Inc. APTO |
Hanmi Pharmaceutical Co., Ltd. | 99,647 19.020% |
0 (Unchanged) |
Filing |
| 2024-02-02 6:05 pm Purchase |
2024-01-31 | 13D | Aptose Biosciences Inc. APTO |
Hanmi Pharmaceutical Co., Ltd. | 99,647 22.170% |
70,175 (+238.11%) |
Filing |
| 2023-09-11 6:23 pm Purchase |
2023-09-06 | 13D | Aptose Biosciences Inc. APTO |
Hanmi Pharmaceutical Co., Ltd. | 29,472 12.070% |
29,472 (New Position) |
Filing |